← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue decreased 50.1% to $34.3M, while Net income decreased 738.0% to ($45.7M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $34.3MWatch
- Profitability — Net income ($45.7M)Watch
- Cash generation — Free cash flow ($65.9M)Note
- Accounting — Formula distress score · no manipulation flag · earnings quality greyWatch
- Insiders — 5 buys; 11 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Business
PRECISION BIOSCIENCES INC: We will need substantial additional funding, and if we are unable to raise a sufficient amount of capital when needed on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.
Where the revenue comes from
Fiscal 2025, as PRECISION BIOSCIENCES INC reports it. History and quarterly detail are in the app.
Leadership changes
From PRECISION BIOSCIENCES INC's own filings, the day they're filed.
- Sam Wadsworth · director · departureeff. 2025-03-04
- Sam Wadsworth · Directors · departureeff. 2025-01-23
- Alan List · Chief Medical Officer · departureeff. 2024-09-13
Latest filings
- 8-K · Company announcement2026-08-24
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-07-27
- 8-K · Company announcement2026-07-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about PRECISION BIOSCIENCES INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.